Contineum Therapeutics is a clinical-stage biotechnology company with zero revenue, entirely dependent on external financing to fund its R&D pipeline. The company's quarterly operating losses have expanded to approximately $17M, while its cash position has plu...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 30, 2026 | -$0.40+10.9% vs -$0.45 | — vs — |
Q2 2026 May 5, 2026 | -$0.39+29.1% vs -$0.55 | — vs — |
Q2 2026 Mar 5, 2026 | -$0.49+2.0% vs -$0.50 | — vs $8M |
Q4 2025 Oct 30, 2025 | -$0.45+22.4% vs -$0.58 | — vs $5M |
Squarepoint Ops LLC lessened its position in shares of Contineum Therapeutics, Inc. (NASDAQ: CTNM) by 80.4% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 11,736 shares of the company's stock after selling 48,108 shares during the period. Squarepoint
Shares of Contineum Therapeutics, Inc. (NASDAQ: CTNM - Get Free Report) dropped 9.9% during mid-day trading on Tuesday after JonesTrading lowered their price target on the stock from $26.00 to $24.00. JonesTrading currently has a buy rating on the stock. Contineum Therapeutics traded as low as $13.08 and last traded at $13.3550. 77,867 shares changed hands
Contineum Therapeutics, Inc. (NASDAQ:CTNM) shares are trading lower on Tuesday as Phase 2 results from a key study disappoint.
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that the MOONLIGHT-1 trial did not achieve its primary efficacy endpoint. The trial evaluated improvement from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Day 5 compared with placebo.
Benchmark CTNM against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Contineum Therapeutics, Inc. (CTNM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $13.12 | $490.51M | -6.05 | — | — | -26.13% | — | |
| $33.62 | $6.94B | -12.14 | — | -7585.86% | -69.59% | — | |
| $8.36 | $437.67M | -1.85 | -92.84% | -80.67% | -14.98% | — | |
| $25.16 | $3.15B | -193.54 | 91.34% | 6.15% | 15.05% | — | |
| $107.39 | $8.83B | -29.10 | -16.72% | -285.41% | -21.5% | — | |
| $52.95 | $4.77B | -51.41 | — | — | -20.02% | — |
Contineum Therapeutics, Inc. (CTNM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Contineum Therapeutics, Inc. (CTNM) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 30, 2026·SEC
Jul 13, 2026·SEC
Jun 26, 2026·SEC
Get notified when CTNM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Contineum Therapeutics, Inc. (CTNM) stock FAQ — growth, dividends, profitability & financials explained
Contineum Therapeutics, Inc. (CTNM) reported a net loss of $57.6M for fiscal year 2025.
Contineum Therapeutics, Inc. (CTNM) has a return on equity (ROE) of -26.1%. Negative ROE indicates the company is unprofitable.
Contineum Therapeutics, Inc. (CTNM) had negative free cash flow of $53.5M in fiscal year 2025, likely due to heavy capital investments.
